Data updated: May 26, 2026
TRILAFON (perphenazine)
Trial Activity: Mature
CNS
Approved 1957-02-27
Development Insights
Janssen Scientific Affairs, LLC conducting 2 trials (25%)
10 indications explored (Broad Platform)
→ schizophrenia (7 trials)
→ perioperative optimization (1 trials)
→ psychotic disorders (1 trials)
3
Indications
--
Phase 3 Trials
69
Years on Market
Details
- Status
- Discontinued
- First Approved
- 1957-02-27
- Routes
- ORAL, INJECTION
- Dosage Forms
- TABLET, EXTENDED RELEASE, INJECTABLE, CONCENTRATE, TABLET, SYRUP
TRILAFON Approval History
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
72 FDA actions from 1957 to 2007
Dec 2007 SUPPL
Label · Labeling
Oct 2001 SUPPL
Label · Labeling
Sep 2001 SUPPL
Label
May 2001 SUPPL
Mfg
Jun 2000 SUPPL
Mfg
Mar 2000 SUPPL
Mfg
Sep 1999 SUPPL
Mfg
Jul 1999 SUPPL
Mfg
Apr 1999 SUPPL
Mfg
Jan 1999 SUPPL
Mfg
Aug 1998 SUPPL
Mfg
Aug 1997 SUPPL
Mfg
Nov 1996 SUPPL
Mfg
Oct 1995 SUPPL
Mfg
Mar 1982 SUPPL
Label
Dec 1958 ORIGINAL
New Form
Jan 1958 ORIGINAL
New Form
Feb 1957 ORIGINAL
New Drug
What TRILAFON Treats
3 FDA approvalsOriginally approved for its first indication in 1957 . Covers 3 distinct patient populations.
- Other (3)
Other
(3 approvals)- • Approved indication (Feb 1957)
- • Approved indication (Jan 1958)
- • Approved indication (Dec 1958)
📋
Clinical Trial Registry
8 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT04606264 | STUDY19030022 | Ph 3 | completed | Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data |
| NCT02431702 DREaM results posted | CR106193 R092670SCH3013 | Ph 3 | completed | A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform |
| NCT02199743 results posted | STU 032012-053 | Ph 4 | completed | Lurasidone Effects on Tissue Glutamate in Schizophrenia |
| NCT02307396 | 1723/1-1 2013-000338-37, DO 1723/1-1 | Ph 4 | completed | Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients |
| NCT02374567 GAP | GAP-2014 | Ph 3 | terminated | Pharmacovigilance in Gerontopsychiatric Patients |
| NCT01157351 results posted | CR015625 R092670SCH3006 | Ph 4 | completed | 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated |
| NCT01193166 | CR017110 R092670SCH4003 | Ph 4 | withdrawn | Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital |
| NCT00802100 COATS results posted | N01 MH090001-02 N01MH90001, N01MH090001 | Ph 4 | completed | Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia |
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
|
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
TRILAFON FDA Label Details
Track TRILAFON with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment